Overview

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Status:
Withdrawn

Trial end date:
2020-12-30

Target enrollment:

Participant gender:

Summary

This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

ImmunityBio, Inc.
NantKwest, Inc.

Treatments:

Albumin-Bound Paclitaxel
Avelumab
Carboplatin
Cyclophosphamide
Docetaxel
Fluorouracil
Paclitaxel